Project Grant R21AI202149
Award Date 8/12/26
Completion Date 7/31/28
Dollars Obligated $253K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $201,875 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate a novel family of alpha-helical peptides that regulate nitrogen metabolism and virulence in pathogenic Enterobacteria, particularly enteroaggregative E. coli (EAEC). The research employs human intestinal organoids alongside infection and fitness mouse models to elucidate the regulatory...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $242,250 on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate microbial drivers of oral vaccine failure in undernourished populations. The research addresses environmental enteric dysfunction, a subclinical intestinal malabsorption syndrome linked to growth stunting and undernutrition. Oral rotavirus vaccination shows significantly reduced efficacy in...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $773,388 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode the cellular networks governing respiratory mucosal IgA immunity. The research addresses mechanisms driving robust respiratory mucosal immunity, particularly IgA responses following infection or vaccination, with the goal of informing next-generation mucosal vaccine strategies against...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $668,128 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop artificial intelligence and machine learning methods for hospital-acquired infection risk prediction, surveillance, and infection control. The recipient will design a multi-disciplinary approach combining deep learning, agent-based modeling, human factors, and systems science to address gaps...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $233,250 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate host-microbe interactions that drive pro-fibrotic macrophage phenotypes in inflammatory bowel disease. The research focuses on defining how adherent-invasive Escherichia coli (AIEC) and other intracellular bacteria manipulate human macrophage signaling and phenotype. The...
- The National Institute of Allergy and Infectious Diseases awarded $886,942 to Benaroya Research Institute At Virginia Mason on June 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of commensal-specific CD8+ T cell differentiation, restraint, and dysregulation in intestinal inflammation. The award supports research into how CD8+ intraepithelial lymphocytes respond to gut microbiota under homeostasis and become dysregulated in...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $236,538 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize biofilm formation mechanisms in Shigella flexneri, the causative agent of bacillary dysentery. The research will identify structural determinants supporting ICSA-mediated bile-salt-dependent biofilm formation and evaluate the role of the ICSA bacterial adaptor protein in both...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $684,405 on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop mucosal immunotherapies targeting recurrent urinary tract infections and inflammatory bowel disease. The funded research advances immunomodulation via self-assembled peptides (ISAP), a platform using modular supramolecular polypeptide nanomaterials designed to elicit neutralizing antibody responses against...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $713,396 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the molecular mechanisms of protective lung resident memory T cells. The project examines how lung tissue-resident memory CD8+ T cells provide broad-spectrum protection against influenza infection, including heterologous protection against variant strains. The research focuses on a...